8189 — Tianjin TEDA Biomedical Engineering Co Income Statement

0.000.00%

Last trade - 00:00

Basic MaterialsHighly SpeculativeSmall CapMomentum Trap

Market Cap
HK$924.06m
Enterprise Value
HK$1.07bn
Revenue
CNY385.48m

Annual income statement for Tianjin TEDA Biomedical Engineering Co, fiscal year end - December 31st, CNY millions except per share, conversion factor applied.

	2020 December 31st	2021 December 31st	R2022 December 31st	2023 December 31st	2024 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	ARS	ARS	ARS	ARS	PRESS
Standards:	HKAS	HKAS	HKAS	HKAS	—
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	369	476	404	398	385
Cost of Revenue
Gross Profit	40.4	45.6	14.8	21.4	20.2
Selling / General / Administrative Expenses
Research And Development
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses	392	501	416	394	408
Operating Profit	-22.9	-24.8	-12.5	4.34	-22.5
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	-50	-44.8	-24.1	-12	-38.2
Provision for Income Taxes
Net Income After Taxes	-50.4	-44.8	-23.5	-11	-38
Minority Interest
Net Income Before Extraordinary Items
Extraordinary Items
Net Income	-48	-42.3	-27.5	-20.2	-27.8
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	-48	-42.3	-27.5	-20.2	-27.8
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	-0.022	-0.015	-0.015	-0.013	-0.015